Royalty Pharma plc — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Royalty Pharma acquires biopharmaceutical royalties and funds development and commercialization in exchange for royalties and other contractual payments.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Total income and other revenues | $568.0 million | $684.0 million |
| Operating income (loss) | $(73.8) million | $479.0 million |
| Net income attributable to Royalty Pharma plc | $4.8 million | $340.8 million |
| Diluted earnings per Class A share | $0.01 | $0.76 |
| Cash provided by operating activities | $664.6 million | $1,033.8 million |
| Portfolio Receipts (non-GAAP) | $717.0 million | $1,131.0 million |
| Royalty Receipts | $704.5 million | $616.1 million |
Operating results were significantly affected by a $583.6 million provision for changes in expected cash flows from royalty assets, a non-cash charge. The filing does not provide a conventional operating margin measure; the royalty-asset provision makes period-to-period operating results especially volatile.
At March 31, 2024, cash and cash equivalents were $843.0 million; total assets were $16.1 billion; financial royalty assets, net, were $14.1 billion; and long-term debt carrying value was $6.14 billion ($6.3 billion principal). The $1.8 billion revolving facility was undrawn. Current assets were $1.56 billion versus current liabilities of $124.6 million. The company paid $93.8 million in Class A dividends and had no share repurchases during the quarter.
Material changes and drivers
- Revenue declined 17.0% year over year, primarily because Q1 2023 included a non-recurring $475 million Zavzpret approval milestone and $153.6 million of related interest income.
- Portfolio Receipts fell 36.6%, largely reflecting the prior-year Zavzpret milestone and an Avillion/Airsupra-related receipt. Royalty Receipts, by contrast, rose 14.3%.
- Royalty growth included Evrysdi (+156.4%), Trelegy (+46.2%) and the cystic fibrosis franchise (+10.6%). Imbruvica receipts fell 12.0% amid competitive pressure; Tysabri declined 2.5% amid pricing pressure and competition.
- The Q1 2024 royalty-asset provision was driven mainly by the cystic fibrosis franchise ($390.5 million) and Crysvita ($128.0 million). For cystic fibrosis, the company used a conservative assumption that royalties apply to tezacaftor, but not the deuterated ivacaftor component, of Vertex’s proposed new triple combination. Royalty treatment is disputed; if the component is determined to be royalty-bearing, the company may record provision income.
- Other income included $77.7 million of equity-security gains and $46.4 million of gains on available-for-sale debt securities. Equity-method investees shifted from $34.6 million of earnings in Q1 2023 to $14.1 million of losses in Q1 2024, largely reflecting Avillion results.
- Operating cash flow decreased $369.2 million year over year, mainly because of lower royalty-asset cash collections and the absence of the prior-year Zavzpret milestone. Cash increased from $477.0 million at year-end 2023 to $843.0 million.
Outlook, risks and notable items
- No numeric earnings or revenue guidance is stated in the provided filing text. Management expects cash, operating cash flows and access to the revolving facility to support operations, planned acquisitions and debt service for the foreseeable future.
- In May 2024, the company announced a planned acquisition of frexalimab royalties and milestones for approximately $525 million, including estimated transaction costs. The candidate is in Phase 3 studies for multiple sclerosis and Phase 2 studies for other indications.
- Q1 investment activity included $93 million invested in royalties, milestones and other contractual receipts. The company acquired an ecopipam royalty for $49 million upfront, with up to $44 million in contingent milestones; it also funded $35 million under its Teva development agreement and had $65 million of unfunded Teva commitments at quarter-end.
- Debt maturities include $1.0 billion in 2025 and $1.0 billion in 2027. The company reported compliance with applicable debt covenants. Interest-rate changes, refinancing access and the ability of royalty assets to generate expected cash flows remain relevant risks.
- Key business risks include product sales, pricing, competition, patent and regulatory changes, clinical or commercial setbacks, portfolio concentration, and the company’s reliance on third-party marketers and its external Manager. Vertex represented 38% of Q1 2024 income and other revenues; its cystic fibrosis franchise accounted for 34% of current financial royalty assets at quarter-end.
- The company disclosed ordinary-course legal proceedings but stated it did not believe their outcomes would materially adversely affect the business; the filing does not provide a clear quantified exposure. Management reported disclosure controls were effective and no material Q1 change in internal control over financial reporting.
Important facts for investors to verify
- How future clinical, regulatory and royalty-term developments affect the $583.6 million provision, especially the disputed royalty scope for Vertex’s new triple-combination therapy.
- Whether growth in royalty receipts continues to offset declines in other portfolio products, and how much reported cash generation depends on one-off milestones or receipts.
- The funding, closing conditions and expected economics of the announced frexalimab transaction, and the progress and remaining commitments for development-stage investments.
- Debt service and covenant capacity in light of $6.3 billion of note principal, upcoming maturities and the variability of royalty cash flows.
- Portfolio concentration, reliance on third-party product marketers, and the effect of future changes in product forecasts on amortized-cost royalty assets and reported earnings.